GENEREX BIOTECHNOLOGY CORP (GNBT) - Description of business
Generex Biotechnology Corporation engages in the research, development, and commercialization of drug delivery systems and technologies for metabolic and immunological diseases. It develops a proprietary platform technology for the delivery of drugs into the human body through the oral cavity. The companyâ€TMs primary product, Oral-lyn is an insulin spray formulation used for the treatment of Type-1 and Type-2 diabetes. It also develops Glucose RapidSpray that delivers glucose through a pump spray to the mouth, as well as morphine and fentanyl by oral formulation and injection for the treatment of moderate to severe breakthrough and postoperative pain. In addition, the company develops technology for the oral administration of molecule drugs, including proteins, peptides, monoclonal antibodies, hormones, and vaccines. It also engages in the research and development of technologies and immunomedicines for the treatment of malignant, infectious, autoimmune, and allergic diseases. The company has collaboration with Fertin Pharma AS for the development of a metformin medicinal chewing gum for the treatment of Type-2 diabetes mellitus and obesity; and an agreement with the Lebanese-Canadian Hospital to conduct a human clinical trial of the Antigen Express synthetic avian influenza vaccine. Generex Biotechnology was founded in 1983 and is based in Toronto, Canada.